Dwrx5003

Phase 1

Daewoong Pharmaceutical Co. LTD.

Dwrx5003 is one of 14 therapeutic programs targeting Obesity & Overweight. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Obesity & OverweightRecruiting

Obesity & OverweightPhase 1

Recruiting

Competition

Competitive Landscape

14 competitors in Obesity & Overweight

#DrugCompanyPhaseTrials

Mazdutide

Eli Lilly

Phase 3

1 2

Ozempic

Novo Nordisk

Phase 2

2 3

AZD6234

AstraZeneca

Phase 2

1 4

AZD9550

AstraZeneca

Phase 2

1 5

Crestor

AstraZeneca

Preclinical

1 6

Semagludtide

Novo Nordisk

Phase 2

1 7

LUM-201

LLumos Pharma

Phase 2

1 8

Enobosarm

VVeru Inc.

Phase 2

1 9

CX11

CCorxel Pharmaceuticals

Phase 1

1 10

Dwrx5003

Daewoong Pharmaceutical Co. LTD.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Obesity & Overweight

NCT07539415

Clinical

Trials by Indication[1]

Obesity & Overweight1 trial

A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

Recruiting· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 1·NCT07539415·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dwrx5003. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dwrx5003. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Daewoong Pharmaceutical Co. LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Daewoong Pharmaceutical Co. LTD.

Dwrx5003

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Obesity & Overweight1 trial

References

Drug Info

Quick Facts

Related News